Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.

Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.

[This corrects the article DOI: 10.1371/journal.pone.0156260.].

Bibliographic Details
Main Authors:	Tsung-Yao Lin, Ku-Chung Chen, Hsing-Jin Eugene Liu, Ann-Jeng Liu, Kun-Li Wang, Chwen-Ming Shih
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5340409?pdf=render

Similar Items

MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
by: Tsung-Yao Lin, et al.
Published: (2016-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
by: Cristina Panuzzo, et al.
Published: (2014-01-01)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023-12-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Detection of BCR-ABL T315i mutation in imatinib resistant chronic myeloid leukemia patients
by: Mardziah M,, et al.
Published: (2019)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
by: Dachuan Zeng, et al.
Published: (2022-05-01)

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
by: Fisihatsion Tadesse, et al.
Published: (2021-12-01)

T-cell receptor (TCR) signaling promotes the assembly of RanBP2/RanGAP1-SUMO1/Ubc9 nuclear pore subcomplex via PKC-θ-mediated phosphorylation of RanGAP1
by: Yujiao He, et al.
Published: (2021-06-01)

Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
by: Yunyi Kang, et al.
Published: (2014-01-01)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
by: Shohei Kawakami, et al.
Published: (2022-01-01)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
by: Liuya Wei, et al.
Published: (2020-09-01)

Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?
by: Simone Bonecker, et al.
Published: (2015-04-01)

Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases
by: Ningshu Huang, et al.
Published: (2018-03-01)

Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation
by: Stephen E. Langabeer, et al.
Published: (2023-01-01)

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
by: Zaborski Margarete, et al.
Published: (2011-02-01)

Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate.
by: Yajuan Li, et al.
Published: (2013-01-01)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
by: Soon Khai Low, et al.
Published: (2022-01-01)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Elias, Marjanu Hikmah, et al.
Published: (2012)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Marjanu Hikmah Elias, et al.
Published: (2012-11-01)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
by: Melissa Pereira Machado, et al.
Published: (2011-06-01)

The GTPase activating Rap/RanGAP domain-like 1 gene is associated with chicken reproductive traits.
by: Xu Shen, et al.
Published: (2012-01-01)

The Cellular Distribution of RanGAP1 Is Regulated by CRM1-Mediated Nuclear Export in Mammalian Cells.
by: Keith Cha, et al.
Published: (2015-01-01)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
by: Federica Loscocco, et al.
Published: (2019-09-01)

Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors.
by: Skobridis, K, et al.
Published: (2010)

α-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib.
by: Massimiliano Bonifacio, et al.
Published: (2012-01-01)

The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
by: Kayastha, G, et al.
Published: (2017)

P685: LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.
by: Chethan R, et al.
Published: (2023-08-01)

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
by: Sílvia Marcé, et al.
Published: (2021-07-01)

PB1964: COMPARISON OF CLINICO-HEMATOLOGICAL PARAMETERS AND MOLECULAR AND CYTOGENETIC RESPONSE OF TWO BCR-ABL FUSION TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB
by: Laabidi Baraa, et al.
Published: (2023-08-01)

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK
by: Cross, N, et al.
Published: (2018)

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
by: Foroni, L, et al.
Published: (2011)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
by: Amin Huma, et al.
Published: (2021-06-01)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
by: Diletta Fontana, et al.
Published: (2021-11-01)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
by: Asako Takeuchi, et al.
Published: (2021-01-01)

Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML
by: Zilin Li, et al.
Published: (2024-04-01)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: M Yaghmaie, et al.
Published: (2005-09-01)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: Yaghmaie M., et al.
Published: (2005-09-01)

Fusion gene bcr-abl: From etiopathogenesis to the management of chronic myeloid leukemia
by: Tri Agusti Sholikah
Published: (2017-04-01)

Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia
by: matteo molica, et al.
Published: (2020-08-01)